EUVIMEDEUVIMED entdecken
Crossref

Paclitaxel Attenuates Atherosclerosis by Suppressing Macrophage Ferroptosis and Improving Lipid Metabolism via the Sirt1/Nrf2/ GPX4 Pathway

Zhenghao Liu iD, Shuxin Cheng, Xiaolin Zheng, Xi Wang, Wenjie Lu, Xule Wang, Liang Pan, Yingguang Shan, Chunguang Qiu

The FASEB Journal · 15.08.2025 · 39 (15)

DOI: 10.1096/fj.202501047rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 08.08.2025. Verfasst von Zhenghao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China. Hauptthemen laut MEDLINE: Paclitaxel, Atherosclerosis, Lipid Metabolism, Signal Transduction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Henan province medical Science and technology tackling program joint co-construction project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is a leading cause of cardiovascular disorders such as coronary heart disease, heart failure, and stroke. Ferroptosis, a novel type of cell death, plays an important role in atherosclerosis progression, especially macrophage ferroptosis. Paclitaxel (PTX) is an antiproliferative drug that has been developed in recent decades and is helpful in the treatment of atherosclerosis. However, the mechanism underlying the anti‐atherosclerotic effects of PTX via inhibition of ferroptosis in macrophages has not been determined. This study aimed to investigate the effect of PTX on ferroptosis in macrophages and determine the underlying mechanism of action in atherosclerosis. In ApoE −/− mice, an atherosclerosis model was established by feeding a high‐fat diet (HFD) for 12 weeks. Then, ApoE −/− mice were treated with PTX and Atorvastatin (positive) for 8 weeks. The effects of PTX on atherosclerosis pathology were evaluated using Oil Red O, Masson's trichrome, and hematoxylin–eosin (HE) staining. To confirm whether PTX inhibited macrophage ferroptosis through the Sirt1/Nrf2/GPX4 pathway, immunofluorescence co‐staining was performed on GPX4 and CD68 (a macrophage marker). Western blotting was used to determine the protein expression levels of the Sirt1/Nrf2/GPX4 pathway and iron metabolism‐related markers. The extent of lipid peroxidation and iron concentration was examined. In addition, we further investigated the potential mechanism of PTX by constructing an atherosclerosis model of RAW 264.7 cells induced by ox‐low‐density lipoprotein (LDL) in vitro. The mechanism through which PTX improves AS was further verified using Sirt1 inhibitors and the knockdown of Sirt1. In vivo studies have shown that PTX significantly improves atherosclerosis progression, which is characterized by reduced lipid deposition, cholesterol crystallization, and increased collagen. Further studies in vivo have shown that PTX inhibits macrophage ferroptosis by activating the Sirt1/Nrf2/GPX4 pathway, thereby effectively improving atherosclerosis. In vitro experiments revealed that PTX decreases reactive oxygen species (ROS) levels and lipid accumulation in ox‐LDL‐induced RAW 264.7 cells. Consistent with in vivo studies, PTX not only changed the iron content and iron metabolism‐related markers in ox‐LDL‐induced RAW 264.7 but also activated the Sirt1/Nrf2/GPX4 pathway. Additionally, the use of Sirt1 inhibitors and the knockdown of Sirt1 identified the potential of PTX to inhibit macrophage ferroptosis by activating the Sirt1/Nrf2/GPX4 pathway. These findings suggest that PTX reduces atherosclerosis by suppressing macrophage ferroptosis and improving lipid metabolism through the activation of the Sirt1/Nrf2/GPX4 pathway and offers new perspectives on the possible application of PTX as a powerful atherosclerosis medication option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelAtherosclerosisLipid MetabolismSignal TransductionMacrophagesFerroptosisMice, KnockoutDiet, High-FatDisease Models, AnimalAtorvastatinAnticholesteremic AgentsAnimalsMiceSirtuin 1NF-E2-Related Factor 2Phospholipid Hydroperoxide Glutathione PeroxidaseMaleMice, Inbred C57BL

Stichwörter der Autor:innen

Sirt1/Nrf2/GPX4atherosclerosisferroptosismacrophagespaclitaxel

Substanzen

PaclitaxelAtorvastatinAnticholesteremic AgentsSirt1 protein, mouseNfe2l2 protein, mouseglutathione peroxidase 4, mouseSirtuin 1NF-E2-Related Factor 2Phospholipid Hydroperoxide Glutathione Peroxidase

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.
  • Department of Cardiovascular Medicine, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, P.R. China.

ORCID-Profile: Zhenghao Liu

Förderung

  • Henan province medical Science and technology tackling program joint co-construction project

Zitieren

APA

Liu, Z., Cheng, S., Zheng, X., Wang, X., Lu, W., Wang, X., Pan, L., Shan, Y., & Qiu, C. (2025). Paclitaxel Attenuates Atherosclerosis by Suppressing Macrophage Ferroptosis and Improving Lipid Metabolism via the Sirt1/Nrf2/ GPX4 Pathway. The FASEB Journal, 39(15). https://doi.org/10.1096/fj.202501047rr

Vancouver

Liu Z, Cheng S, Zheng X, Wang X, Lu W, Wang X, et al. Paclitaxel Attenuates Atherosclerosis by Suppressing Macrophage Ferroptosis and Improving Lipid Metabolism via the Sirt1/Nrf2/ GPX4 Pathway. The FASEB Journal. 2025;39(15). doi:10.1096/fj.202501047rr

BibTeX
@article{Liu2025,
  author = {Liu, Zhenghao and Cheng, Shuxin and Zheng, Xiaolin and Wang, Xi and Lu, Wenjie and Wang, Xule and Pan, Liang and Shan, Yingguang and Qiu, Chunguang},
  title = {Paclitaxel Attenuates Atherosclerosis by Suppressing Macrophage Ferroptosis and Improving Lipid Metabolism via the Sirt1/Nrf2/ GPX4 Pathway},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {15},
  doi = {10.1096/fj.202501047rr}
}
Kostenlos starten →